REGENXBIO Inc.
RGNX
$9.01
$0.9011.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 155.78M | 156.72M | 83.33M | 84.33M | 89.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 155.78M | 156.72M | 83.33M | 84.33M | 89.04M |
| Cost of Revenue | -23.28M | -17.91M | -15.30M | -28.83M | -25.07M |
| Gross Profit | 179.06M | 174.62M | 98.63M | 113.15M | 114.11M |
| SG&A Expenses | 74.70M | 73.68M | 71.62M | 74.95M | 78.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 930.00K | 914.00K | 865.00K | 150.00K | 333.00K |
| Total Operating Expenses | 320.38M | 314.07M | 314.57M | 324.41M | 332.01M |
| Operating Income | -164.60M | -157.36M | -231.25M | -240.08M | -242.96M |
| Income Before Tax | -175.57M | -157.69M | -227.10M | -238.96M | -241.23M |
| Income Tax Expenses | -- | -- | -- | -152.00K | -152.00K |
| Earnings from Continuing Operations | -175.57 | -157.69 | -227.10 | -238.81 | -241.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -175.57M | -157.69M | -227.10M | -238.81M | -241.08M |
| EBIT | -164.60M | -157.36M | -231.25M | -240.08M | -242.96M |
| EBITDA | -148.75M | -141.37M | -215.03M | -223.55M | -226.02M |
| EPS Basic | -3.44 | -3.11 | -4.61 | -5.03 | -5.27 |
| Normalized Basic EPS | -2.15 | -1.94 | -2.85 | -3.07 | -3.21 |
| EPS Diluted | -3.44 | -3.11 | -4.61 | -5.03 | -5.27 |
| Normalized Diluted EPS | -2.15 | -1.94 | -2.85 | -3.07 | -3.21 |
| Average Basic Shares Outstanding | 204.52M | 203.63M | 198.01M | 191.14M | 184.28M |
| Average Diluted Shares Outstanding | 204.59M | 203.71M | 198.01M | 191.14M | 184.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |